Literature DB >> 29778353

Tackling progression in multiple sclerosis.

Jeremy Chataway1.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29778353     DOI： 10.1016/S1474-4422(18)30158-3

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  4 in total

Review 1.  Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview.

Authors:  Floriana De Angelis; Domenico Plantone; Jeremy Chataway
Journal:  CNS Drugs       Date:  2018-06       Impact factor: 5.749

Review 2.  Disease Progression in Multiple Sclerosis: A Literature Review Exploring Patient Perspectives.

Authors:  Elisabeth G Celius; Heidi Thompson; Maija Pontaga; Dawn Langdon; Alice Laroni; Stanca Potra; Trishna Bharadia; David Yeandle; Jane Shanahan; Pieter van Galen; Nektaria Alexandri; Jürg Kesselring
Journal:  Patient Prefer Adherence       Date:  2021-01-08       Impact factor: 2.711

3.  lncRNA-GM targets Foxo1 to promote T cell-mediated autoimmunity.

Authors:  Yali Chen; Juan Liu; Xiaomin Zhang; Ha Zhu; Yujia Wang; Zhiqing Li; Yanfang Liu; Shuo Liu; Shuxun Liu; Nan Li; Kun Chen; Xuetao Cao
Journal:  Sci Adv       Date:  2022-08-05       Impact factor: 14.957

Review 4.  Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015-2020.

Authors:  Leoni Rolfes; Marc Pawlitzki; Steffen Pfeuffer; Niklas Huntemann; Heinz Wiendl; Tobias Ruck; Sven G Meuth
Journal:  BioDrugs       Date:  2020-10       Impact factor: 5.807
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.